CD274 and non-small cell lung carcinoma: While most of PD-1/PD-L1 inhibitors were first approved in the treatment of advanced NSCLC, the greater part of studies paid attention to more detailed investigation of PD-L1 expression and TME association in these patients [18,20,21,22].